Rivaroxaban
Rivaroxaban is an oral anticoagulant used in the prevention and treatment of thromboembolic disease.
Rivaroxaban is an oral anticoagulant used in the prevention and treatment of thromboembolic disease. It belongs to the class of direct oral anticoagulants (DOACs) and acts by selectively inhibiting factor Xa, a key enzyme in the coagulation cascade that promotes thrombin generation and fibrin clot formation. By reducing factor Xa activity, rivaroxaban lowers the blood’s ability to clot and is used in a range of cardiovascular and thrombosis-related settings.
Clinically, rivaroxaban is relevant in conditions such as non-valvular atrial fibrillation, venous thromboembolism, and selected high-risk cardiovascular populations where anticoagulation is indicated. Its use is also closely tied to bleeding management and reversal strategies, including the use of andexanet alfa in severe hemorrhage. In recent research, rivaroxaban has also been studied alongside apixaban and aspirin in comparative effectiveness, dual-pathway inhibition, and pharmacokinetic interaction contexts.
Where the papers sit
11 papers from the last 6 months study rivaroxaban directly · updated from PubMed 3 Oct 2026
Study type 1 clinical trial · 4 observational · 3 human data · 1 preclinical · 2 unclassified
Themes one subject · 1 new direction
Those 11 are all about one subject.
-
Real-World Anticoagulant Use
Real-world anticoagulant use centers on rivaroxaban’s effectiveness, tolerability, and bleeding risk across atrial fibrillation and special populations. Comparative data weigh rivaroxaban against warfarin and other direct oral anticoagulants, while patient satisfaction, cost, renal injury, and pediatric outcomes broaden assessment beyond stroke prevention. Severe bleeding and overdose repeatedly shift attention to emergency management, including andexanet alfa and hemoadsorption with CytoSorb, although evidence remains case-based. Pharmacokinetic measurement, formulation behavior, and plaque inflammation are emerging adjuncts rather than a single treatment direction.
CytoSorb gives rivaroxaban management a rescue-device role beyond pharmacologic reversal
The life-threatening gastrointestinal bleeding case following rivaroxaban administration found that conventional resuscitative and endoscopic measures were insufficient, while andexanet alfa was unavailable because of cost; CytoSorb-based hemoperfusion nevertheless achieved bleeding control when emergency surgery was considered too risky. This introduces extracorporeal adsorption as a potential rescue strategy for rivaroxaban-associated hemorrhage, rather than treating management as dependent on standard reversal agents alone 42696504Sep.
Papers
The 11 papers from the last 6 months that study rivaroxaban directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Real-World Anticoagulant Use (11)
- Kidney injury associated with direct oral anticoagulants: a comparative study of direct thrombin inhibitors and factor Xa inhibitors based on literature and database analysis. Renal failure · 10 Sept 2026 PMID 42717832
- CytoSorb Application for Successful Control of Life-Threatening Gastrointestinal Bleeding Following Rivaroxaban Administration. The American journal of case reports · 4 Sept 2026 PMID 42696504
- Patient Self-Reported Global Satisfaction With Rivaroxaban in Patients With Atrial Fibrillation: A Comparison Between Oral Anticoagulation-Naïve Versus Oral Anticoagulation-Experienced Patients. Clinical cardiology · 2 Sept 2026 PMID 42683599
- Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings - A Real-World Retrospective Cohort Study. Hamostaseologie · 29 Jul 2026 PMID 42526884
- Real-world comparative safety and effectiveness of rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation: a prospective cohort study. Current medical research and opinion · 25 Jul 2026 PMID 42499238
- Effect of low-dose rivaroxaban plus aspirin on 18F-FDG PET/CT-detectable carotid plaque inflammation: a randomized trial. European heart journal. Cardiovascular Imaging · 13 Jul 2026 PMID 42439277
- Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in a Belgian healthcare setting. Journal of medical economics · 1 Jun 2026 PMID 42223336
- Predicting plasma concentration-time profiles of orally disintegrating tablets with delayed absorption under fed conditions without water. International journal of pharmaceutics · 4 May 2026 PMID 42082063
- Emergency reversal of Rivaroxaban with Andexanet alfa in a child with hemorrhagic brain metastasis from Wilms tumor. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2 May 2026 PMID 42069956
- Microcolumn Liquid Chromatography-Atmospheric Pressure Chemical Ionisation Tandem Mass Spectrometric Determination of Nitrosamine Impurities From Pharmaceutical Products. Rapid communications in mass spectrometry : RCM · 1 May 2026 PMID 42065343
- A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11). British journal of clinical pharmacology · 24 Apr 2026 PMID 42031672
By study type
Clinical trials (1)
- Effect of low-dose rivaroxaban plus aspirin on 18F-FDG PET/CT-detectable carotid plaque inflammation: a randomized trial. European heart journal. Cardiovascular Imaging · 13 Jul 2026 PMID 42439277
Observational studies and case reports (4)
- CytoSorb Application for Successful Control of Life-Threatening Gastrointestinal Bleeding Following Rivaroxaban Administration. The American journal of case reports · 4 Sept 2026 PMID 42696504
- Patient Self-Reported Global Satisfaction With Rivaroxaban in Patients With Atrial Fibrillation: A Comparison Between Oral Anticoagulation-Naïve Versus Oral Anticoagulation-Experienced Patients. Clinical cardiology · 2 Sept 2026 PMID 42683599
- Emergency reversal of Rivaroxaban with Andexanet alfa in a child with hemorrhagic brain metastasis from Wilms tumor. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2 May 2026 PMID 42069956
- A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11). British journal of clinical pharmacology · 24 Apr 2026 PMID 42031672
Human data, design not indexed (3)
- Kidney injury associated with direct oral anticoagulants: a comparative study of direct thrombin inhibitors and factor Xa inhibitors based on literature and database analysis. Renal failure · 10 Sept 2026 PMID 42717832
- Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in a Belgian healthcare setting. Journal of medical economics · 1 Jun 2026 PMID 42223336
- Predicting plasma concentration-time profiles of orally disintegrating tablets with delayed absorption under fed conditions without water. International journal of pharmaceutics · 4 May 2026 PMID 42082063
Preclinical: animal, cell and lab studies (1)
- Microcolumn Liquid Chromatography-Atmospheric Pressure Chemical Ionisation Tandem Mass Spectrometric Determination of Nitrosamine Impurities From Pharmaceutical Products. Rapid communications in mass spectrometry : RCM · 1 May 2026 PMID 42065343
Unclassified: not yet indexed with MeSH (2)
- Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings - A Real-World Retrospective Cohort Study. Hamostaseologie · 29 Jul 2026 PMID 42526884
- Real-world comparative safety and effectiveness of rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation: a prospective cohort study. Current medical research and opinion · 25 Jul 2026 PMID 42499238
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-12 by GPT. Drafted by language models from published abstracts; not medical advice.